

ICICI Securities Limited
is the author and
distributor of this report

Q2FY22 result review
and reco change

Specialty Chemicals

Target price: Rs3,100

Earnings revision

(%)	FY22E	FY23E
Sales	↓ 0.7	↑ 1.5
EBITDA	↓ 8.8	↓ 0.1
EPS	↓ 10.4	↓ 0.1

Shareholding pattern

	Mar '21	Jun '21	Sep '21
Promoters	30.2	30.2	30.2
Institutional investors	40.9	41.8	41.6
MFs and other	13.4	12.4	12.5
Insurance Cos.	0.0	0.0	0.0
FII	27.5	29.4	29.1
Others	28.9	28.0	28.2

Source: NSE

Price chart



Research Analyst:

Sanjesh Jain

sanjesh.jain@icicisecurities.com
+91 22 6637 7153

Akash Kumar

akash.kumar@icicisecurities.com
+91 22 2277 7637

INDIA



Navin Fluorine International

REDUCE

Upgrade from Sell

Rs3,502

Revenue growth still some time away

Navin Fluorine International's (NFIL) Q2FY22 EBITDA dip of 10.6% YoY shows it was walking a tight rope on revenue growth with limited capacity in specialty chemicals, and volatile CRAMS revenue. NFIL is also catching up with peers and is accelerating investment in capabilities by adding a technology team and expanding R&D. Company is in a sweet spot to monetise fluorination opportunities, but the evolution would be gradual compared to impatient market expectations. Acceleration in revenues is expected only after stabilisation of HPP and MPP-2 plants, which we believe could take at least 3-4 quarters (H2FY23). Despite higher investments, NFIL has been able to maintain margins, and higher realisation in ref-gas should offset any potential cost headwinds in specialty chemicals in H2FY22 in our view. We have cut our FY22E EPS by 10% and maintained FY23E estimates. We upgrade NFIL to **REDUCE** (from Sell) with an unchanged target price of Rs3,100 (40x FY23E EPS) as valuations (P/E) remain unattractive at 45x FY23E and 39xFY24E.

► **Unimpressive revenue growth.** Standalone revenues rose 5.4% YoY to Rs3.2bn, (+3.4% QoQ) driven by 32.7% YoY growth in inorganic fluoride segment to Rs650mn, and specialty chemical revenue growth of 19.6% YoY (down 8.3% QoQ) to Rs1.22bn. CRAMS revenue fell 17.2% YoY to Rs820mn on high base, and ref-gas revenue declined 5.2% YoY to Rs550mn. NFIL has guided for FY22 CRAMS revenue run-rate to remain stable at US\$10mn, while ref-gas should benefit from hardening of realisations. Efforts to drive new products in specialty chemicals continue, and new MPP plant should help expand revenues, which will start only from FY23. In the near term, NFIL has initiated price hike to pass on rise in input costs in specialty chemicals, but it may not be margin-accretive. Inorganic fluoride segment benefited from strong traction in underlying products as efforts on new product introductions continue.

► **Gross margin stable.** Gross margin rose 50bps QoQ to 55.4%, but was low YoY on lower contribution from CRAMS. EBITDA dipped 10.6% YoY to Rs835mn due to significant inflation in employee cost (+39% YoY) on building capabilities across technology and R&D, as well as retention benefits offered to key business people. Other expenses were up 15.4% YoY due to higher freight cost, and one-off consultancy fees (Rs50mn). EBITDA margin stood at 25.8%, up 90bps QoQ. Net profit declined 7.8% YoY to Rs621mn. Company's CWIP stood at Rs3.3bn, and it believes it is on track to commence HPP and MPP plants by Q1FY23.

► **Investing in capabilities.** NFIL has been investing in its technology development team, which is responsible to take the plant from lab to commercial scale. The technology team is a completely new addition for the company. It has hired 50 people in the team who should come handy during HPP plant knowledge transfer from buyer. It is expanding its R&D team from 120 to 200 eventually, and has plans for a new R&D facility likely in Mumbai, which will focus on specialty chemicals and new initiatives. NFIL is expanding its business development team, particularly in the US, to drive CRAMS revenue.

Market Cap	Rs173bn/US\$2.3bn	Year to Mar	FY21	FY22E	FY23E	FY24E
Reuters/Bloomberg	NAFL.BO/NFIL IN	Revenue (Rs bn)	11.8	14.0	20.7	23.4
Shares Outstanding (mn)	49.5	Net Income (Rs bn)	2.4	2.7	3.8	4.4
52-week Range (Rs)	4140/2036	Recurring EPS (Rs)	52.0	54.6	77.5	88.7
Free Float (%)	69.8	% Chg YoY	(37.0)	5.0	41.8	14.6
FII (%)	29.1	P/E (x)	67.3	64.1	45.2	39.5
Daily Volume (US\$/'000)	15,790	CEPS (Rs)	61.0	63.4	93.5	106.9
Absolute Return 3m (%)	(8.2)	EV/E (x)	54.0	47.2	31.5	26.6
Absolute Return 12m (%)	72.3	Dividend Yield (%)	0.3	0.5	0.7	0.8
Sensex Return 3m (%)	17.6	RoCE (%)	11.8	13.6	17.1	16.7
Sensex Return 12m (%)	52.7	RoE (%)	16.9	15.6	19.6	19.6

Please refer to important disclosures at the end of this report

► **Other highlights.** **1)** Capex for new projects in HPP and MPP-2 has been progressing on expected lines. **2)** Company plans debottlenecking in CRAMS cGMP-3 plant, which should take six months to execute; cGMP-4 would follow as the order pipeline increases. New plant execution would take 12-15 months. **3)** Revenue from the new initiatives will take at least 2-3 years as they have long approval and audit cycle. **4)** Repeat order in CRAMS is driven from same products, and also new product addition from same customer. It has seen one product entering phase-3 while a few are reaching advance stage in phase-2 where material requirement is higher. **5)** Company plans to take price hike to pass on raw material inflation in specialty chemicals. **6)** Ref-gas price negotiation has started and the benefit should flow from next quarter. **7)** Employee cost will remain at 11-12% of sales for next few years.

Table 1: NFIL (consolidated financials)

Rs mn	Q2FY21	Q3FY21	Q4FY21	Q1FY22	Q2FY22	QoQ (%)	YoY (%)
Net revenue	3,189	3,091	3,364	3,265	3,390	3.8	6.3
Cost of Goods sold	1,432	1,425	1,607	1,484	1,524	2.7	6.4
Gross profit	1,757	1,666	1,758	1,781	1,866	4.7	6.2
<i>Gross profit margin (%)</i>	55.1	53.9	52.2	54.6	55.0		
Employee cost	340	362	369	438	436	(0.4)	28.4
<i>% of revenue</i>	10.7	11.7	11.0	13.4	12.9		
Other expenses	510	499	546	566	588	3.9	15.2
<i>% of revenue</i>	16.0	16.1	16.2	17.3	17.3		
Total expenses	850	861	915	1,004	1,024	2.0	20.5
EBITDA	907	805	842	778	842	8.2	(7.2)
<i>EBITDA margin (%)</i>	28.4	26.0	25.0	23.8	24.8		
Depreciation	109	110	116	120	119	(1.1)	9.3
EBIT	799	695	727	658	723	9.9	(9.5)
<i>EBIT margin (%)</i>	25.0	22.5	21.6	20.1	21.3		
Other income	97	99	233	89	105	18.0	8.5
Finance cost	4	4	8	5	4	(20.6)	1.6
PBT	891	790	952	742	824	11.1	(7.6)
Tax expenses	247	226	375	182	192	5.0	(22.5)
<i>ETR (%)</i>	27.7	28.6	39.4	24.6	23.3		
Exceptional item							
Profit from JV	34	24	16	(0)	(0)		
PAT	678	589	593	559	632	13.1	(6.8)
<i>Net profit margin (%)</i>	21.3	19.1	17.6	17.1	18.7		
Recurring EPS (Rs)	13.7	11.9	12.0	11.3	12.8	13.1	(6.8)

Source: Company data, I-Sec research

Table 2: NFIL (standalone financials)

Rs mn	Q2FY21	Q3FY21	Q4FY21	Q1FY22	Q2FY22	QoQ (%)	YoY (%)
Net revenue	3,077	2,966	3,240	3,139	3,244	3.4	5.4
Cost of Goods sold	1,367	1,359	1,532	1,416	1,447	2.1	5.9
Gross profit	1,710	1,607	1,708	1,722	1,798	4.4	5.1
<i>Gross profit margin (%)</i>	55.6	54.2	52.7	54.9	55.4		
Employee cost	283	294	325	396	394	(0.5)	39.1
<i>% of revenue</i>	9.2	9.9	10.0	12.6	12.1		
Other expenses	492	490	541	546	568	4.0	15.4
<i>% of revenue</i>	16.0	16.5	16.7	17.4	17.5		
Total expenses	775	784	866	942	962	2.1	24.1
EBITDA	935	823	842	780	835	7.1	(10.6)
<i>EBITDA margin (%)</i>	30.4	27.8	26.0	24.8	25.8		
Depreciation	100	101	106	109	110	0.5	9.6
EBIT	835	722	736	671	726	8.2	(13.0)
<i>EBIT margin (%)</i>	27.1	24.3	22.7	21.4	22.4		
Other income	88	91	197	76	85	11.9	(3.1)
Finance cost	3	3	6	4	3	(28.7)	(6.4)
PBT	920	810	927	743	808	8.8	(12.1)
Exceptional item	-	-	662	-	-		
Tax expenses	246	223	373	179	187	4.8	(24.0)
<i>ETR (%)</i>	26.8	27.6	40.2	24.1	23.2		
PAT	673	587	1,216	564	621	10.0	(7.8)
<i>Net profit margin (%)</i>	21.9	19.8	37.5	18.0	19.1		
Recurring EPS (Rs)	13.6	11.9	11.2	11.4	12.5	10.0	(7.8)

Source: Company data, I-Sec research

Table 3: NFIL – segmental revenues



Rs mn	Q2FY21	Q3FY21	Q4FY21	Q1FY22	Q2FY22	QoQ (%)	YoY (%)
Refrigerants	580	470	580	590	550	(6.8)	(5.2)
Inorganic Fluorides	490	570	590	560	650	16.1	32.7
Specialty Chemicals	1,020	1,220	1,310	1,330	1,220	(8.3)	19.6
CRAMS	990	710	750	670	820	22.4	(17.2)
Total revenue	3,080	2,970	3,230	3,150	3,240	2.9	5.2
Contribution (%)							
Refrigerants	18.8	15.8	18.0	18.7	17.0		
Inorganic Fluorides	15.9	19.2	18.3	17.8	20.1		
Specialty Chemicals	33.1	41.1	40.6	42.2	37.7		
CRAMS	32.1	23.9	23.2	21.3	25.3		

Source: Company data, I-Sec research

Table 4: NFIL – geographic revenues

Rs mn	Q2FY21	Q3FY21	Q4FY21	Q1FY22	Q2FY22	QoQ (%)	YoY (%)
Domestic							
Refrigerants	275	249	328	348	330	(5.2)	20.2
Inorganic Fluorides	188	359	367	504	585	16.1	211.8
Specialty Chemicals	668	785	818	705	659	(6.5)	(1.4)
CRAMS	-	-	-	-	-		
Total Domestic	1,130	1,394	1,514	1,557	1,574	1.1	39.2
Exports							
Refrigerants							
Inorganic Fluorides	306	221	252	242	220	(9.1)	(28.0)
Specialty Chemicals	302	211	223	56	65	16.1	(78.5)
CRAMS	352	445	492	625	561	(10.2)	59.5
Total Exports	990	710	750	670	820	22.4	(17.2)

Source: Company data, I-Sec research

Chart 1: Export realisation for R-22**Chart 2: Fluorspar (key raw material) prices****Table 5: Earnings revision**

(Rs mn)	Revised		Earlier		% change	
	FY22E	FY23E	FY22E	FY23E	FY22E	FY23E
Revenue	13,999	20,715	14,102	20,412	(0.7)	1.5
EBITDA	3,598	5,520	3,945	5,524	(8.8)	(0.1)
EBITDA margin (%)	25.7	26.6	28.0	27.1		
PAT	2,703	3,834	3,018	3,836	(10.4)	(0.1)
EPS (Rs)	55	77	61	78	(10.4)	(0.1)

Source: I-Sec research

Financial summary

Table 6: Profit & Loss statement

(Rs mn, year ending March 31)

	FY21	FY22E	FY23E	FY24E
Operating Income (Sales)	11,794	13,999	20,715	23,361
Operating Expenses	8,701	10,401	15,195	16,971
EBITDA	3,093	3,598	5,520	6,390
% margins	26.2	25.7	26.6	27.4
Depreciation & Amortisation	442	437	792	898
Net Interest	18	11	11	11
Other Income	790	480	433	425
Recurring PBT	3,423	3,629	5,150	5,905
Add: Extraordinaries	155	-	-	-
Less: Taxes	1,108	926	1,316	1,513
- Current tax	1,108	926	1,316	1,513
- Deferred tax	-	-	-	-
Add: Share of JV	105	-	-	-
Net Income (Reported)	2,575	2,703	3,834	4,392
Recurring Net Income	2,420	2,703	3,834	4,392

Source: Company data, I-Sec research

Table 7: Balance sheet

(Rs mn, year ending March 31)

	FY21	FY22E	FY23E	FY24E
Assets				
Total Current Assets	11,634	9,769	11,546	16,781
of which cash & cash equiv.	5,439	2,552	733	4,459
Total Current Liabilities & Provisions	2,403	2,802	4,002	4,489
Net Current Assets	9,231	6,967	7,544	12,293
Investments	1,530	1,530	1,530	1,530
of which				
Strategic/Group	547	547	547	547
Other Marketable	983	983	983	983
Net Fixed Assets	4,933	9,082	13,177	11,486
Goodwill	878	878	878	878
Total Assets	16,572	18,456	23,128	26,186
Liabilities				
Borrowings	25	25	2,025	2,025
Deferred tax liability	207	207	207	207
Minority Interest	-	-	-	-
Equity Share Capital	99	99	99	99
Face Value per share (Rs)	2.0	2.0	2.0	2.0
Reserves & Surplus	16,240	18,126	20,798	23,856
Net Worth	16,339	18,225	20,897	23,955
Total Liabilities	16,572	18,457	23,129	26,187

Source: Company data, I-Sec research

Table 8: Quarterly trend

(Rs mn, year ending March 31)

	Dec-20	Mar-21	Jun-21	Sep-21
Net sales	3,091	3,364	3,265	3,390
% growth (YoY)	18.7	21.6	51.9	6.3
EBITDA	805	842	778	842
Margin (%)	26.0	25.0	23.8	24.8
Other income	99	233	89	105
Add: Extra ordinaries	-	155	-	-
Net profit	589	748	559	632

Source: Company data

Table 9: Cashflow statement

(Rs mn, year ending March 31)

	FY21	FY22E	FY23E	FY24E
Operating Cashflow	3,627	2,672	4,204	4,877
Working Capital Changes	(1,255)	(622)	(2,396)	(1,023)
Capital Commitments	(987)	(4,586)	(4,887)	793
Free Cashflow	1,386	(2,536)	(3,079)	4,647
Cashflow from Investing Activities	(1,384)	480	433	425
Issue of Share Capital	14	-	-	-
Inc (Dec) in Borrowings	11	-	2,000	-
Dividend paid & Others	(476)	(830)	(1,173)	(1,345)
Chg. in Cash & Bank balance	(449)	(2,886)	(1,819)	3,727

Source: Company data, I-Sec research

Table 10: Key ratios

(Year ending March 31)

	FY21	FY22E	FY23E	FY24E
Per Share Data (in Rs.)				
Recurring EPS	52.0	54.6	77.5	88.7
Reported EPS	52.0	54.6	77.5	88.7
Recurring Cash EPS	61.0	63.4	93.5	106.9
Dividend per share (DPS)	11.0	16.5	23.5	26.9
Book Value per share (BV)	330.1	368.2	422.2	484.0
Growth Ratios (%)				
Operating Income	11.1	18.7	48.0	12.8
EBITDA	17.4	16.3	53.4	15.8
Recurring Net Income	(37.0)	5.0	41.8	14.6
Diluted Recurring EPS	(37.0)	5.0	41.8	14.6
Diluted Recurring CEPS	(32.3)	4.1	47.3	14.3
Valuation Ratios (% YoY)				
P/E	67.3	64.1	45.2	39.5
P/CEPS	57.5	55.2	37.5	32.8
P/BV	10.6	9.5	8.3	7.2
EV / EBITDA	54.0	47.2	31.5	26.6
EV / Operating Income	14.2	12.1	8.4	7.3
EV / Operating FCF	113.8	(67.0)	(56.4)	36.6
Operating Ratios				
Other Income / PBT (%)	23.1	13.2	8.4	7.2
Effective Tax Rate (%)	32.4	25.5	25.6	25.6
NWC / Total Assets (%)	22.9	23.9	29.4	29.9
Inventory Turnover (days)	55.8	50.6	50.0	50.8
Receivables (days)	87.9	89.2	91.4	92.5
Payables (days)	33.2	35.1	35.1	35.2
Net Debt/EBITDA Ratio (x)	(2.1)	(1.0)	0.1	(0.5)
Capex % of sales	8.4	32.8	23.6	(3.4)
Profitability Ratios (%)				
Recur. Net Income Margins	21.8	19.3	18.5	18.8
RoCE	11.8	13.6	17.1	16.7
RoIC	18.2	19.1	19.6	19.6
RoNW	16.9	15.6	19.6	19.6
Dividend Yield	0.3	0.5	0.7	0.8
Gross Margins	54.4	55.4	55.8	56.5
EBITDA Margins	26.2	25.7	26.6	27.4

Source: Company data, I-Sec research

This report may be distributed in Singapore by ICICI Securities, Inc. (Singapore branch). Any recipients of this report in Singapore should contact ICICI Securities, Inc. (Singapore branch) in respect of any matters arising from, or in connection with, this report. The contact details of ICICI Securities, Inc. (Singapore branch) are as follows: Address: 10 Collyer Quay, #40-92 Ocean Financial Tower, Singapore - 049315, Tel: +65 6232 2451 and email: navneet_babbar@icicisecuritiesinc.com, Rishi_agrawal@icicisecuritiesinc.com.

"In case of eligible investors based in Japan, charges for brokerage services on execution of transactions do not in substance constitute charge for research reports and no charges are levied for providing research reports to such investors."

*New I-Sec investment ratings (all ratings based on absolute return; All ratings and target price refers to 12-month performance horizon, unless mentioned otherwise)
BUY: >15 return; ADD: 5 to 15 return; HOLD: Negative 5 to Positive 5 return; REDUCE: Negative 5 to Negative 15 return; SELL: < negative 15 return*

ANALYST CERTIFICATION

I/We, Sanjesh Jain, PGDM; Akash Kumar, MBA; authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of the ICICI Securities Inc. It is also confirmed that above mentioned Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months and do not serve as an officer, director or employee of the companies mentioned in the report.

Terms & conditions and other disclosures:

ICICI Securities Limited (ICICI Securities) is a full-service, integrated investment banking and is, inter alia, engaged in the business of stock brokering and distribution of financial products.

ICICI Securities is Sebi registered stock broker, merchant banker, investment adviser, portfolio manager and Research Analyst. ICICI Securities is registered with Insurance Regulatory Development Authority of India Limited (IRDAI) as a composite corporate agent and with PFRDA as a Point of Presence. ICICI Securities Limited Research Analyst SEBI Registration Number – INH000000990. ICICI Securities Limited SEBI Registration is INZ000183631 for stock broker. ICICI Securities is a subsidiary of ICICI Bank which is India's largest private sector bank and has its various subsidiaries engaged in businesses of housing finance, asset management, life insurance, general insurance, venture capital fund management, etc. ("associates"), the details in respect of which are available on www.icicibank.com.

ICICI Securities is one of the leading merchant bankers/ underwriters of securities and participate in virtually all securities trading markets in India. We and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Investment Research Department. ICICI Securities and its analysts, persons reporting to analysts and their relatives are generally prohibited from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

Recommendation in reports based on technical and derivative analysis centre on studying charts of a stock's price movement, outstanding positions, trading volume etc as opposed to focusing on a company's fundamentals and, as such, may not match with the recommendation in fundamental reports. Investors may visit icicidirect.com to view the Fundamental and Technical Research Reports.

Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein.

ICICI Securities Limited has two independent equity research groups: Institutional Research and Retail Research. This report has been prepared by the Institutional Research. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the Retail Research.

The information and opinions in this report have been prepared by ICICI Securities and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of ICICI Securities. While we would endeavour to update the information herein on a reasonable basis, ICICI Securities is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent ICICI Securities from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or ICICI Securities policies, in circumstances where ICICI Securities might be acting in an advisory capacity to this company, or in certain other circumstances.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purposes and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. ICICI Securities will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. ICICI Securities accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice.

ICICI Securities or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

ICICI Securities or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction.

ICICI Securities or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the companies mentioned in the report in the past twelve months.

ICICI Securities encourages independence in research report preparation and strives to minimize conflict in preparation of research report. ICICI Securities or its associates or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither ICICI Securities nor Research Analysts and their relatives have any material conflict of interest at the time of publication of this report.

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

ICICI Securities or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the report as of the last day of the month preceding the publication of the research report.

Since associates of ICICI Securities and ICICI Securities as an entity are engaged in various financial service businesses, they might have financial interests or beneficial ownership in various companies including the subject company/companies mentioned in this report.

ICICI Securities may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.

Neither the Research Analysts nor ICICI Securities have been engaged in market making activity for the companies mentioned in the report.

We submit that no material disciplinary action has been taken on ICICI Securities by any Regulatory Authority impacting Equity Research Analysis activities.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject ICICI Securities and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.

This report has not been prepared by ICICI Securities, Inc. However, ICICI Securities, Inc. has reviewed the report and, in so far as it includes current or historical information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.